ATE209038T1 - Pharmazeutisches präparat, das heparin, heparinfragmente oder -derivate in kombination mit glycerinestern enthält - Google Patents

Pharmazeutisches präparat, das heparin, heparinfragmente oder -derivate in kombination mit glycerinestern enthält

Info

Publication number: ATE209038T1
Authority: AT; Austria
Prior art keywords: heparin; pct; derivatives; combination; administration
Prior art date: 1993-06-18

Application number

AT94919936T

Other languages

English (en)

Inventor

Monica Einarsson

Original Assignee

Pharmacia Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-06-18

Filing date

1994-06-16

Publication date

2001-12-15

1994-06-16 Application filed by Pharmacia Ab filed Critical Pharmacia Ab

2001-12-15 Application granted granted Critical

2001-12-15 Publication of ATE209038T1 publication Critical patent/ATE209038T1/de

Links

HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title abstract 2
229960002897 heparin Drugs 0.000 title abstract 2
229920000669 heparin Polymers 0.000 title abstract 2
239000002634 heparin fragment Substances 0.000 title abstract 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical class OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title 1
239000002628 heparin derivative Substances 0.000 title 1
239000000825 pharmaceutical preparation Substances 0.000 title 1
239000000203 mixture Substances 0.000 abstract 3
238000010521 absorption reaction Methods 0.000 abstract 2
239000003623 enhancer Substances 0.000 abstract 2
230000006978 adaptation Effects 0.000 abstract 1
239000000654 additive Substances 0.000 abstract 1
239000000969 carrier Substances 0.000 abstract 1
235000014113 dietary fatty acids Nutrition 0.000 abstract 1
239000003085 diluting agent Substances 0.000 abstract 1
229930195729 fatty acid Natural products 0.000 abstract 1
239000000194 fatty acid Substances 0.000 abstract 1
150000004665 fatty acids Chemical class 0.000 abstract 1
150000002314 glycerols Chemical class 0.000 abstract 1
210000004400 mucous membrane Anatomy 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000007920 subcutaneous administration Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

AT94919936T 1993-06-18 1994-06-16 Pharmazeutisches präparat, das heparin, heparinfragmente oder -derivate in kombination mit glycerinestern enthält ATE209038T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE19939302135A SE9302135D0 (sv)	1993-06-18	1993-06-18	New pharmaceutical composition
PCT/SE1994/000595 WO1995000152A1 (en)	1993-06-18	1994-06-16	Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol esters

Publications (1)

Publication Number	Publication Date
ATE209038T1 true ATE209038T1 (de)	2001-12-15

Family

ID=20390356

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94919936T ATE209038T1 (de)	1993-06-18	1994-06-16	Pharmazeutisches präparat, das heparin, heparinfragmente oder -derivate in kombination mit glycerinestern enthält

Country Status (10)

Country	Link
US (1)	US5714477A (de)
EP (1)	EP0706398B1 (de)
JP (1)	JP3953510B2 (de)
AT (1)	ATE209038T1 (de)
DE (1)	DE69429169T2 (de)
DK (1)	DK0706398T3 (de)
ES (1)	ES2168299T3 (de)
PT (1)	PT706398E (de)
SE (1)	SE9302135D0 (de)
WO (1)	WO1995000152A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6008228A (en) *	1995-06-06	1999-12-28	Hoffman-La Roche Inc.	Pharmaceutical compositions containing proteinase inhibitors
SE9602145D0 (sv) *	1996-05-31	1996-05-31	Astra Ab	New improved formulation for treatment of thromboembolism
US8119159B2 (en) *	1999-02-22	2012-02-21	Merrion Research Iii Limited	Solid oral dosage form containing an enhancer
US7658938B2 (en)	1999-02-22	2010-02-09	Merrion Reasearch III Limited	Solid oral dosage form containing an enhancer
US20070148228A1 (en) *	1999-02-22	2007-06-28	Merrion Research I Limited	Solid oral dosage form containing an enhancer
US6761903B2 (en)	1999-06-30	2004-07-13	Lipocine, Inc.	Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6458383B2 (en)	1999-08-17	2002-10-01	Lipocine, Inc.	Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
EP1192187A1 (de) *	1999-06-30	2002-04-03	Hamilton Civic Hospitals Research Development, Inc.	Heparinzusammensetzungen, die gerinnselzugehörige gerinnungsfakoren verhindert
US6982281B1 (en) *	2000-11-17	2006-01-03	Lipocine Inc	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20030236236A1 (en) *	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
CN1183965C (zh)	2000-02-04	2005-01-12	尤尼金实验室公司	鼻内降钙素制剂
DE10026699A1 (de) *	2000-05-30	2001-12-06	Basf Ag	Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
US20040038932A1 (en) *	2000-09-08	2004-02-26	Jack Hirsh	Antithrombotic compositions
WO2002092616A1 (en) *	2001-05-11	2002-11-21	Orasense, Ltd.	Antisense permeation enhancers
WO2002092070A1 (en) *	2001-05-11	2002-11-21	Elan Corporation, Plc	Isostearic acid salts as permeation enhancers
WO2003009817A2 (en) *	2001-07-25	2003-02-06	Protein Design Labs, Inc.	Stable lyophilized pharmaceutical formulation of igg antibodies
SE521676C2 (sv) *	2002-01-02	2003-11-25	Dilafor Ab	Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
EP1542704A1 (de) *	2002-04-18	2005-06-22	Stephen H. Embury	VERFAHREN UND ZUSAMMENSETZUNG ZUR PRûVENTION VON SCHMERZEN BEI SICHELZELL-PATIENTEN
US20060003002A1 (en) *	2003-11-03	2006-01-05	Lipocine, Inc.	Pharmaceutical compositions with synchronized solubilizer release
MXPA06011871A (es) *	2004-04-15	2007-10-08	Chiasma Inc	Composiciones capaces de facilitar la penetracion a traves de una barrera biologica.
US20070219131A1 (en) *	2004-04-15	2007-09-20	Ben-Sasson Shmuel A	Compositions capable of facilitating penetration across a biological barrier
AU2005240206B2 (en) *	2004-05-06	2011-04-07	Emisphere Technologies, Inc.	Solid dosage form of wetted heparin
NZ551196A (en)	2004-05-14	2010-08-27	Emisphere Tech Inc	Compounds and compositions for delivering active agents
US20050282775A1 (en) *	2004-06-16	2005-12-22	Paringenix, Inc.	Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US7563780B1 (en) *	2004-06-18	2009-07-21	Advanced Cardiovascular Systems, Inc.	Heparin prodrugs and drug delivery stents formed therefrom
US20070021378A1 (en) *	2005-07-22	2007-01-25	The Regents Of The University Of California	Heparin compositions and selectin inhibition
US20070154546A1 (en) *	2005-12-30	2007-07-05	Zhang Jack Y	Sustained release pharmaceutical compositions
ES2426445T3 (es) *	2006-04-07	2013-10-23	Merrion Research Iii Limited	Forma de dosificación oral sólida que contiene un potenciador
CA2654566A1 (en) *	2006-06-09	2007-12-21	Merrion Research Iii Limited	Solid oral dosage form containing an enhancer
WO2009137080A1 (en) *	2008-05-07	2009-11-12	Merrion Research Iii Limited	Compositions of gnrh related compounds and processes of preparation
NZ591810A (en)	2008-09-17	2012-12-21	Chiasma Inc	Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
US20100215743A1 (en) *	2009-02-25	2010-08-26	Leonard Thomas W	Composition and drug delivery of bisphosphonates
JP2013514976A (ja)	2009-12-16	2013-05-02	ノッドファーマシューティカルズ，インコーポレイテッド	経口薬物送達のための組成物および方法
US20110142889A1 (en) *	2009-12-16	2011-06-16	Nod Pharmaceuticals, Inc.	Compositions and methods for oral drug delivery
AU2010332797B2 (en)	2009-12-18	2015-05-28	Catalent Pharma Solutions Gmbh	Pharmaceutical oral dosage form containing a synthetic oligosaccharide
US20110182985A1 (en) *	2010-01-28	2011-07-28	Coughlan David C	Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) *	2010-03-26	2015-07-28	Merrion Research Iii Limited	Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
US8802114B2 (en)	2011-01-07	2014-08-12	Merrion Research Iii Limited	Pharmaceutical compositions of iron for oral administration
KR102165348B1 (ko)	2012-05-09	2020-10-14	캔텍스 파마슈티칼즈, 인크.	골수억제의 치료
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
JP7211704B2 (ja)	2015-01-29	2023-01-24	ノヴォノルディスクアー／エス	Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
PL3253401T3 (pl)	2015-02-03	2025-08-04	Amryt Endo, Inc.	Leczenie akromegalii oktreotydem doustnym
WO2016133910A1 (en)	2015-02-17	2016-08-25	Cantex Pharmaceuticals, Inc.	Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
US20160361322A1 (en)	2015-06-15	2016-12-15	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en)	2016-11-28	2023-01-24	Lipocine Inc.	Oral testosterone undecanoate therapy
EP3824296A4 (de)	2018-07-20	2022-04-27	Lipocine Inc.	Lebererkrankung
AU2019368537B2 (en) *	2018-10-25	2025-05-08	Cubopharm Pty Ltd	Composition that forms liquid crystalline particles
US11141457B1 (en)	2020-12-28	2021-10-12	Amryt Endo, Inc.	Oral octreotide therapy and contraceptive methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3510561A (en) *	1965-05-20	1970-05-05	Canada Packers Ltd	Sulfone-enhanced heparin absorption through mucous membranes
JPS53107408A (en) *	1977-02-28	1978-09-19	Yamanouchi Pharmaceut Co Ltd	Micellar preparation for rectal infusion
CA1136620A (en) *	1979-01-08	1982-11-30	Ulf P.F. Lindahl	Heparin fragments having selective anticoagulation activity
DE3171774D1 (en) *	1980-03-31	1985-09-19	Teijin Ltd	Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
JPS6028972A (ja) *	1983-06-29	1985-02-14	Kyowa Hakko Kogyo Co Ltd	ジベンゾ［ｂ，ｅ］オキセピン誘導体
DE3331009A1 (de) *	1983-08-27	1985-03-14	Basf Ag, 6700 Ludwigshafen	Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
FR2616661B1 (fr) *	1987-06-19	1991-06-07	Doutremepuich Christian	Composition a base de mucopolysaccharides hepariniques, active par voie orale
DE3805523A1 (de) *	1988-02-22	1989-10-05	Schur Pharmazeutika Gmbh & Co	Pharmazeutische praeparate zur transdermalen applikation von heparin

1993
- 1993-06-18 SE SE19939302135A patent/SE9302135D0/xx unknown
1994
- 1994-06-16 ES ES94919936T patent/ES2168299T3/es not_active Expired - Lifetime
- 1994-06-16 US US08/569,087 patent/US5714477A/en not_active Expired - Fee Related
- 1994-06-16 WO PCT/SE1994/000595 patent/WO1995000152A1/en not_active Ceased
- 1994-06-16 PT PT94919936T patent/PT706398E/pt unknown
- 1994-06-16 EP EP94919936A patent/EP0706398B1/de not_active Expired - Lifetime
- 1994-06-16 DK DK94919936T patent/DK0706398T3/da active
- 1994-06-16 AT AT94919936T patent/ATE209038T1/de not_active IP Right Cessation
- 1994-06-16 DE DE69429169T patent/DE69429169T2/de not_active Expired - Fee Related
- 1994-06-16 JP JP50271195A patent/JP3953510B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69429169T2 (de)	2002-06-20
SE9302135D0 (sv)	1993-06-18
DK0706398T3 (da)	2002-05-21
WO1995000152A1 (en)	1995-01-05
US5714477A (en)	1998-02-03
EP0706398A1 (de)	1996-04-17
ES2168299T3 (es)	2002-06-16
DE69429169D1 (de)	2002-01-03
JP3953510B2 (ja)	2007-08-08
PT706398E (pt)	2002-05-31
EP0706398B1 (de)	2001-11-21
JPH09501652A (ja)	1997-02-18

Legal Events

Date	Code	Title	Description
2002-05-15	UEP	Publication of translation of european patent specification
2010-03-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE209038T1 (de)	2001-12-15	Pharmazeutisches präparat, das heparin, heparinfragmente oder -derivate in kombination mit glycerinestern enthält
NO963639D0 (no)	1996-08-30	Sublingual eller buckal farmasöytisk blanding
TR200001982T2 (tr)	2001-02-21	Farmasötik vurulu salınımlı oral dozaj şekli.
EP1153924A3 (de)	2001-11-21	Substutuierte 1,3-Oxathiolane mit antiviralen Eigenschaften
AU1540392A (en)	1992-11-17	Benzopyranones, methods of manufacture and use thereof
PT831882E (pt)	2005-01-31	Composicoes de segmentos de fibra de colagenio reconstituido e metodos de preparacao das mesmas
BR9810450A (pt)	2000-09-05	Derivados de ácido barbitúrico com atividade antimetastática e antitumor
ES479272A1 (es)	1980-01-16	Un procedimiento para la preparacion de esteres de acidos 17beta-tiocarboxilicos de 4-halo-3-oxoandrost-4-enos.
EE9700187A (et)	1998-02-16	Farmatseutiline kompositsioon peroraalseks manustamiseks, selle valmistamismeetod ja kasutamine
DE69713300D1 (de)	2002-07-18	Benzopyran derivate mit leukotrien-antagonistischer wirkung
EE04606B1 (et)	2006-04-17	H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
ATE148990T1 (de)	1997-03-15	Ebastin oder ebastin-analoga enthaltende arzneimittel
ATE46146T1 (de)	1989-09-15	Phenylpiperidinderivat und seine salze, ihre herstellung, sie enthaltende zusammensetzungen und ihre therapeutische verwendung.
TR200000153T2 (tr)	2000-07-21	İl-5 inhibite eden 6-azaurasil türevleri.
ATE159511T1 (de)	1997-11-15	Derivate von n,n,n',n'-tetrasubstituierten 1,2- ethylendiamin-verbindungen
ATE59295T1 (de)	1991-01-15	Prazosin-pirbuterol-mischung zur bronchendilatation.
DE69931504D1 (de)	2006-06-29	Zusammensetzungen zur linderung der nebeneffekte des interleukin-2
DK0937057T3 (da)	2003-05-05	Hidtil ukendte (-)-enantiomerer af cis-3,4-chromanderivater anvendelige i forebyggelse eller behandling af østrogenrelaterede sygdomme eller syndromer
CA2434775A1 (en)	2002-07-25	Compounds for use in the treatment of skin conditions
SE8303031D0 (sv)	1983-05-30	Improved steroid esters preparation
ATE145197T1 (de)	1996-11-15	Lagerstabile lösungen von carbonisiertem magnesiumethylat in ethanol sowie deren herstellung und verwendung
DK521389A (da)	1989-12-15	Praeparat til behandling af adrenoleukodystrofi
SE7603556L (sv)	1976-10-22	Protein med tymushormonliknande verkan, sett att framstella detdamma, och kompositioner innehallande proteinet till anvendning for att hoja immunforsvaret
ES2069500B1 (es)	1996-03-01	Perfeccionamientos introducidos en el objeto de la patente espa¦ola n 9201983 por "procedimiento para la obtencion de benzoxazinas utiles para la sintesis de oflexacina, levofloxacina y derivados.
FR2592653A1 (fr)	1987-07-10	Derives de chromene, procede d'obtention et compositions pharmaceutiques.